About Epigenomics
Epigenomics is a company based in Berlin (Germany) founded in 1998.. Epigenomics has raised $46.67 million across 12 funding rounds from investors including European Commission, 3i Group and European Union. The company has 32 employees as of December 31, 2021. Epigenomics offers products and services including Investment Services. Epigenomics operates in a competitive market with competitors including Guardant Health, GRAIL, Foundation Medicine, ArcherDX and Natera, among others.
- Headquarter Berlin, Germany
- Employees 32 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Epigenomics Ag
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$46.67 M (USD)
in 12 rounds
-
Latest Funding Round
$6.77 M (USD), Post-IPO
Jan 07, 2021
-
Investors
European Commission
& 9 more
-
Employee Count
32
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Epigenomics
Epigenomics offers a comprehensive portfolio of products and services, including Investment Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Services for acquiring and managing investments in cancer detection technologies.
Funding Insights of Epigenomics
Epigenomics has successfully raised a total of $46.67M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6.77 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Post-IPO — $6.8M
-
First Round
First Round
(14 Nov 2000)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Post-IPO - Epigenomics | Valuation |
investors |
|
| Mar, 2020 | Amount | Post-IPO - Epigenomics | Valuation |
investors |
|
| Nov, 2019 | Amount | Post-IPO - Epigenomics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Epigenomics
Epigenomics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include European Commission, 3i Group and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Private equity firm focused on mid-market businesses
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Epigenomics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Epigenomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Epigenomics Comparisons
Competitors of Epigenomics
Epigenomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Foundation Medicine, ArcherDX and Natera, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Circulating tumor DNA is screened for early cancer detection.
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Epigenomics
Frequently Asked Questions about Epigenomics
When was Epigenomics founded?
Epigenomics was founded in 1998 and raised its 1st funding round 2 years after it was founded.
Where is Epigenomics located?
Epigenomics is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
Who is the current CEO of Epigenomics?
Greg Hamilton is the current CEO of Epigenomics.
Is Epigenomics a funded company?
Epigenomics is a funded company, having raised a total of $46.67M across 12 funding rounds to date. The company's 1st funding round was a Post-IPO of $5.3M, raised on Nov 14, 2000.
How many employees does Epigenomics have?
As of Dec 31, 2021, the latest employee count at Epigenomics is 32.
What does Epigenomics do?
Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for the screening and diagnosis of cancer. Their product portfolio includes Epi proColon, a blood-based test for the early detection of colorectal cancer and Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer.Their development pipeline also contains tests for screening, monitoring, diagnosis and prognosis assessment in colorectal and lung cancer.
Who are the top competitors of Epigenomics?
Epigenomics's top competitors include Guardant Health, GRAIL and Strand Life Sciences.
What products or services does Epigenomics offer?
Epigenomics offers Investment Services.
Who are Epigenomics's investors?
Epigenomics has 10 investors. Key investors include European Commission, 3i Group, European Union, Abingworth, and Deutsche Balaton.